The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 27, Issue 12, 2012, Pages 1248-1257

  Rosenberg, P B ^a,b   Mielke, M M ^a,b,c   Han, D ^a,b   Leoutsakos, J S ^a,b,d   Lyketsos, C G ^a,b,d   Rabins, P V ^a,b   Zandi, P P ^d   Breitner, J C S ^e,f   Norton, M C ^g   Welsh Bohmer, K A ^h   Zuckerman, I H ⁱ   Rattinger, G B ⁱ   Green, R C ^j,k   Corcoran, C ^g   Tschanz, J T ^g  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Mayo Clinic College of Medicine   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g UTAH STATE UNIVERSITY   (United States)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

Alzheimer's disease; antidepressants; antipsychotics; cognition; epidemiology; neuropsychiatric symptoms; pharmacoepidemiology; psychosocial function; SSRI

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHOLINESTERASE INHIBITOR; MEMANTINE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL DEMENTIA RATING SUM OF BOXES; COGNITION; COGNITIVE DEFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROPSYCHIATRIC INVENTORY; NEUROPSYCHIATRY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITION; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES;

EID: 84868581939     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.3769     Document Type: Article

References (39)

1. Breitner JC, Wyse BW, Anthony JC, et al., 1999. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology 53: 321-331.
2. Cummings JL, Mega M, Gray K, et al., 1994. The neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314.
3. Drye LT, Martin BK, Frangakis CE, et al., 2010. Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study +/- 2 (DIADS-2)? Int J Geriatr Psychiatry. DOI: 10.1002/gps.2565.
4. Ellul J, Archer N, Foy CM, et al., 2007. The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration. J Neurol Neurosurg Psychiatry 78: 233-239. DOI: 10.1136/jnnp.2006.104034; jnnp.2006.104034 [pii].
5. Ensrud KE, Blackwell T, Mangione CM, et al., 2003. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 163: 949-957. DOI: 10.1001/archinte.163.8.949.
6. Folstein MF, Folstein SE, McHugh PR,. 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198. 0022-3956(75)90026-6 [pii].
7. Gruber-Baldini AL, Stuart B, Zuckerman IH, Simoni-Wastila L, Miller R,. 2007. Treatment of dementia in community-dwelling and institutionalized medicare beneficiaries. J Am Geriatr Soc 55: 1508-1516. DOI: 10.1111/j.1532-5415.2007. 01387.x.
8. Kamble P, Chen H, Sherer JT, Aparasu RR,. 2009. Use of antipsychotics among elderly nursing home residents with dementia in the US: an analysis of National Survey Data. Drugs Aging 26: 483-492. DOI: 10.2165/00002512-200926060- 00005.
9. Lauterbach EC, Victoroff J, Coburn KL, et al., 2010. Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J Neuropsychiatry Clin Neurosci 22: 8-18. DOI: 10.1176/appi.neuropsych.22.1.8.
10. Liu Y, Yoo MJ, Savonenko A, et al., 2008. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J Neurosci 28: 13805-13814. DOI: 10.1523/JNEUROSCI.4218- 08.2008.
11. Livingston G, Walker AE, Katona CL, Cooper C,. 2007. Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study. J Neurol Neurosurg Psychiatry 78: 25-29. DOI: 10.1136/jnnp.2006.094342.
12. Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST,. 1999. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol 56: 1266-1272.
13. Lopez OL, Schwam E, Cummings J, et al., 2010. Predicting cognitive decline in Alzheimer's disease: an integrated analysis. Alzheimers Dement 6: 431-439. DOI: 10.1016/j.jalz.2010.04.003.
14. Lyketsos CG, Galik E, Steele C, et al., 1999. The general medical health rating: a bedside global rating of medical comorbidity in patients with dementia. J Am Geriatr Soc 47: 487-491.
15. Malberg JE,. 2004. Implications of adult hippocampal neurogenesis in antidepressant action. J Psychiatry Neurosci 29: 196-205.
16. McKhann G, Drachman D, Folstein M, et al., 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 34: 939-944.
17. Mielke MM, Rosenberg PB, Tschanz J, et al., 2007. Vascular factors predict rate of progression in Alzheimer disease. Neurology 69: 1850-1858. DOI: 10.1212/01.wnl.0000279520.59792.fe.
18. Morris JC,. 1993. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43: 2412-2414.
19. Morris JC,. 1997. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 9 Suppl 1: 173-176; discussion 177-8.
20. Morris JC, Ernesto C, Schafer K, et al., 1997. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology 48: 1508-1510.
21. Murphy CF, Alexopoulos GS,. 2004. Longitudinal association of initiation/perseveration and severity of geriatric depression. Am J Geriatr Psychiatry 12: 50-56.
22. Nelson RL, Guo Z, Halagappa VM, et al., 2007. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol 205: 166-176. DOI: 10.1016/j.expneurol.2007.01.037.
23. Palmer K, Di Iulio F, Varsi AE, et al., 2010. Neuropsychiatric predictors of progression from amnestic-mild cognitive impairment to Alzheimer's disease: the role of depression and apathy. J Alzheimers Dis. DOI: 10.3233/JAD-2010-1352.
24. Pavlik VN, Doody RS, Massman PJ, Chan W,. 2006. Influence of premorbid IQ and education on progression of Alzheimer's disease. Dement Geriatr Cogn Disord 22: 367-377. DOI: 10.1159/000095640; DEM2006022004367 [pii].
25. Pollock BG, Mulsant BH, Rosen J, et al,. 2002. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 159: 460-465.
26. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT, Memantine MEM-MD-12 Study Group. 2008. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 5: 83-89.
27. Rosenberg PB, Drye LT, Martin BK, et al., 2010. Sertraline for the treatment of depression in Alzheimer's disease. Am J Geriatric Psychiatry 18: 136-145.
28. Rountree SD, Chan W, Pavlik VN, et al., 2009. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther 1: 7. DOI: 10.1186/alzrt7.
29. Schneider LS, Dagerman KS, Insel P,. 2005. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294: 1934-1943. DOI: 10.1001/jama.294.15.1934.
30. Simoni-Wastila L, Ryder PT, Qian J, et al., 2009. Association of antipsychotic use with hospital events and mortality among medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry 17: 417-427. DOI: 10.1097/JGP.0b013e31819b8936.
31. Sink KM, Holden KF, Yaffe K,. 2005. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293: 596-608. DOI: 10.1001/jama.293.5.596.
32. Steinberg M, Shao H, Zandi P, et al., 2008. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 23: 170-177. DOI: 10.1002/gps.1858.
33. Sultzer DL, Davis SM, Tariot PN, et al., 2008. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 165: 844-854. DOI: 10.1176/appi.ajp.2008.07111779.
34. Tschanz JT, Corcoran CD, Schwartz S, et al., 2011. Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression Study. Am J Geriatr Psychiatry 19: 532-542. DOI: 10.1097/JGP.0b013e3181faec23.
35. Wang PS, Schneeweiss S, Avorn J, et al., 2005. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353: 2335-2341. DOI: 10.1056/NEJMoa052827.
36. Weinshenker D,. 2008. Functional consequences of locus coeruleus degeneration in Alzheimer's disease. Curr Alzheimer Res 5: 342-345.
37. Weintraub D, Rosenberg PB, Drye LT, et al., 2010. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry 18: 332-340. DOI: 10.1097/JGP.0b013e3181cc0333.
38. Woolcott JC, Richardson KJ, Wiens MO, et al., 2009. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169: 1952-1960. DOI: 10.1001/archinternmed.2009.357.
39. Zandi PP, Anthony JC, Hayden KM, et al., 2002. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 59: 880-886.